AI assistant
El.En. — Investor Presentation 2015
Dec 1, 2015
4393_cp_2015-12-01_9ed0ac9e-216b-4bc0-b011-9cd52513f443.pdf
Investor Presentation
Open in viewerOpens in your device viewer
COMPANY PRESENTATION
Q3 2015 FINANCIAL RESULTS
INTERMONTE
Dec. 1st , 2015
Disclaimer
Certain statements in this slide show, including those addressing the Company's beliefs, plans, objectives, estimates or expectations of possible future results or events, are forward-looking statements. Forward-looking statements involve known or unknown risks, including general economic and business conditions, and conditions in the industry we operate and may be affected should our assumptions turn out to be inaccurate. Consequently, no forward-looking statement can be guaranteed and actual future results, performance, or achievements may vary materially from those expressed or implied by such forward-looking statements. The Company undertakes no obligation about the contents nor to update the forward-looking statements to reflect events or circumstances that may arise after the date hereof.
Summary
- 1.LASERS AND LASER APPLICATIONS
- 2.THE GLOBAL LASER MARKET
- 3.EL.EN. GROUP
- 4.Q3 - 2015 FINANCIAL RESULTS
- 5.2015 GUIDANCE
- 6.EL.EN. STOCK, MULTIPLES & COMPARABLES
Lasers and Laser Applications
LASER
Light Amplification by Stimulated Emission of Radiation
MEDICALLASER Systems
INDUSTRIALLASER Systems
Medical and Aest. Applications
Industrial lasers applications
Hot Products
Monna Lisa Touch
Discovery Pico
Motus AX
Multipulse HoPLUS
The Global Laser Market
The MEDICAL Laser Market
| d i l l e c a a s e r s |
d h t y e n u s e , |
\$ ( h 2 0 1 9 o u g |
) i l l i m o n s |
|---|---|---|---|
| 2 0 3 1 |
2 0 1 4 |
2 0 9 1 |
C G % A R |
| 2 0 1 4 2 0 1 9 - |
|||
| 7 5 8 |
8 1 3 |
1 2 1 9 |
8 4 % , |
| 8 9 5 |
1 0 2 4 |
2 0 9 7 |
% 1 5 4 , |
| 2 0 9 |
2 4 4 |
6 2 3 |
% 2 0 7 , |
| 9 9 |
1 1 5 |
2 4 7 |
6 % 1 5 , |
| 9 6 1 1 |
2 9 1 5 |
8 4 1 5 |
3 8 % 1 , |
| b | r |
Global market for medical lasers by region, through 2019 (\$ millions)
| k M S t t a r e e g m e n |
2 0 1 3 |
2 0 1 4 |
2 0 1 9 |
C A G R % |
|
|---|---|---|---|---|---|
| 2 0 2 0 9 1 4 1 - |
|||||
| d d S U C a n a n a a |
9 0 2 |
0 0 8 1 |
8 0 1 7 |
3 2 % 1 , |
|
| E u r o p e |
9 5 7 |
6 4 7 |
1 2 0 8 |
1 3 3 % , |
|
| f A i P i i s a a c c |
3 5 2 |
3 9 9 |
8 4 9 |
1 6 3 % , |
|
| h O t e r |
1 2 8 |
1 4 1 |
2 5 8 |
% 1 2 8 , |
|
| l T t o a |
1 9 6 1 |
2 1 9 5 |
4 1 8 5 |
% 1 3 8 , |
The INDUSTRIAL Laser Market
Global market and forecast for high power laser systems by application (by value)
| l B V y a u e |
l b l G M o a a |
( k i l E U R M t r e |
( ) C A G R % |
||
|---|---|---|---|---|---|
| 2 0 1 3 |
2 0 1 6 |
2 0 2 0 |
2 0 1 3 2 0 1 6 - |
2 0 1 6 2 0 2 0 - |
|
| C i t t u n g |
2 4 0 8 |
3 0 1 4 |
3 9 6 5 |
7 8 , |
7 1 , |
| l d d W i B i e n g a n r a z n g |
1 2 4 9 |
1 6 0 5 |
2 2 3 1 |
8 7 , |
8 6 , |
| f d h S O t t t t u r a c e r e a m e n a n e r |
5 0 |
6 3 |
8 6 |
8 3 , |
8 1 , |
| l T t o a |
3 7 0 7 |
4 6 8 2 |
6 2 8 2 |
8 1 , |
7 6 , |
El.En. Group
Group Overview
High –Tech laser photonics Group
Develops, manufactures and distributes laser sources and laser systems for medical and industrial applications
Know-how based on 30 years stratification of multidisciplinary experience
Q3 2015: Consolidated Revenues of €156 mln, up 25% YoY
985 employees
Global positioning
El.En. Group
Strategic Strengths
Multidisciplinary and multifacility R&D activity: sources, systems, applications
Industrial
Combine High tech laser source development with flexible production facilities in high growth areas
Medical
Technological and clinical innovation improving performance andbroadening the application scope of our laser systems
- Maximize market penetration by multi brand approach
- Open new market segments by developing innovative applications
- Leverage worldwide distribution with multi brand approach
Consolidated Revenuesand EBIT
R&D Activity
Clinical trials and validations of new therapeutic laser treatments and research on new applications of laser- tissue interaction
Broadening Mona Lisa Touch Clinical studiesCentral role of PHOTOBIOLABClinical studies on cutaneous ulcers New Pico second laser platform New approach to laser hair removalPatents developmentIncreased power of RF laser sourcesInnovative beam delivery and focusing systems
Q3 -2015 Financial Results
ConsolidatedP&L
| / E 0 0 0 u r o |
/ / 3 0 0 9 1 4 |
/ / 3 0 0 9 1 5 |
% V a r. |
||
|---|---|---|---|---|---|
| R e v e n u e s |
1 2 4 6 1 6 |
1 0 0 0 % , |
1 5 6 0 0 6 |
1 0 0 0 % , |
2 5 2 % , |
| i G r o s s m a r g n |
5 7 2 7 4 |
% 4 6 0 , |
7 0 2 3 6 |
% 4 5 0 , |
% 2 2 6 , |
| E B I T D A |
1 1 9 6 4 |
9 6 % , |
1 9 3 1 0 |
1 2 4 % , |
6 1 4 % , |
| E B I T ( * ) |
1 0 5 3 2 |
8 5 % , |
1 6 1 9 3 |
1 0 4 % , |
5 3 7 % , |
| P I t ( ) r e a x n c o m e |
1 8 7 4 4 |
% 1 5 0 , |
1 7 1 9 1 |
% 1 1 0 , |
% 8 3 - , |
(*) 2014 Non recurring: +1,5 mln of euros. 2014 EBIT% w/o non recurring: 7,3% and var% 15/14 adj.: +79%(**) 2014 Total one time and non recurring: +9,0mln of euros on pretax income and var% 15/14 adj.: +80%
Net financialposition
| '0 0 0 E u r o |
/ / 3 1 1 2 1 4 |
/ / 3 0 0 9 1 5 |
V a r. |
|---|---|---|---|
| f l i i i i N t t e n a n c a p o s o n : |
4 7 1 1 6 |
2 3 0 7 5 |
2 4 0 4 1 |
Decrease due to:
- - 10,5 mln: temporary investments in non current assets
- - 5,3 mln: dividends paid
- - 5,0 mln: capex
- - 3,0 mln: cash flow from operations
2015 Guidance
2015 Guidance
Sales: >210 mln +17%
EBIT: >20 mln
El.En. Stock, Multiples & Comparables
Euro
El.En. Multiples
| k h l d 's h * S i E t t o c o e r q p e r s a r e u y |
3 4 |
|
|---|---|---|
| / k l d i j. P B V A r c e o o a e u |
2 9 1, |
|
| / ( ) V I 8 % I E E B T 5 E B T |
4 7, 7 |
|
| / l ( l ) S 8 % S E V 5 a e s a e s |
0, 8 7 |
|
| l. k C E E M t n. a r e a p. |
2 0 9, 9 @ |
€ 3, 0 4 5 |
| f i i l i i N t t e n a n c a p o s o n |
@ 2 3, 1 |
/ / 3 0 0 9 1 5 |
| / l l i i i F t t t n a n c a n v e s m e n s m e r m |
1 0, 6 @ |
/ / 3 0 0 9 1 5 |
| k l f h 0 M 1, C t a r e a e o m m n o s r e s a r e s v u y u |
3 9, @ 1 |
\$ 8 4 1, 4 / ( d ) U 1, 0 6 E u r o s = |
| i l E V t n e r p r s e a u e |
1 3 7, 1 |
|
| k h l d 's i f i i i S E t t t t o c o e r q u y n e o m n o r e s, * ( ) i h h k l C t t t w y n o s u r e s a r e s a m a r e v a u e |
1 6 2, 1 |
El.En. Comparables
| Pr ice |
Re ve nu e |
Va % r. |
E B I T |
E B I T % |
M K. Ca p. |
E V |
/ le E V Sa s |
/ E V E B I T |
/ k P Bo o |
|
|---|---|---|---|---|---|---|---|---|---|---|
| Se 3 0, 2 0 1 5 t p |
Re ve nu e |
( *) |
( *) |
lu Va e |
||||||
| / d l he M ica Ae ic t t e s |
||||||||||
| Sy ne ro n |
\$ 7, 6 4 |
\$ 1 9 8. 9 5 9 |
1 0 % |
\$ ( ) 8. 4 7 6 |
-4 % |
\$ 2 6 9. 2 1 0 |
\$ 1 8 9. 6 8 8 |
0, 7 2 |
n. a. |
1, 2 6 |
| l iq Ze t |
\$ 3 0, 7 5 |
\$ 1 7 7. 1 9 1 |
% 4 3 |
\$ 1. 8 9 5 |
% 1 |
\$ 1. 2 2 0. 0 0 0 |
\$ 1. 1 7 3. 4 4 0 |
4, 9 7 |
4 6 4, 4 2 |
1 5, 4 2 |
| Cu te ra |
\$ 1 4, 4 7 |
\$ 6 4. 1 9 7 |
2 3 % |
\$ ( ) 6. 1 8 5 |
-1 0 % |
\$ 1 8 1. 9 1 0 |
\$ 1 3 4. 1 6 6 |
1, 5 5 |
n. a. |
3, 6 9 |
| la B io se |
\$ 0, 9 0 |
\$ 3 3. 9 5 8 |
-1 % |
\$ ( ) 1 7. 6 4 0 |
-5 2 % |
\$ 5 4. 6 2 0 |
\$ 3 9. 4 2 6 |
0, 8 7 |
n. a. |
2, 0 7 |
| Cy no su re |
\$ 4 1, 4 8 |
\$ 2 3 7. 0 2 0 |
1 5 % |
\$ 1 4. 5 2 9 |
6 % |
\$ 9 2 9. 2 5 0 |
\$ 8 2 7. 0 0 8 |
2, 6 2 |
4 2, 6 9 |
2, 3 8 |
| du l In ia tr s |
||||||||||
| ho I P G P ics Co to n |
\$ 8 9, 7 6 |
\$ 6 7 7. 6 0 0 |
2 0 % |
\$ 2 5 9. 0 0 0 |
3 8 % |
\$ 4. 7 5 0. 0 0 0 |
\$ 4. 0 9 9. 0 2 8 |
4, 5 4 |
1 1, 8 7 |
3, 9 1 |
| f in in Ro -S ar |
\$ 2 8, 5 4 |
\$ 3 9 7. 2 5 3 |
% -3 |
\$ 4 8. 8 9 9 |
% 1 2 |
\$ 8 0 6. 2 8 0 |
\$ 6 3 0. 7 1 8 |
1, 1 9 |
9, 6 7 |
1, 4 9 |
| du Pr im In ie tr a s |
€ 1 4, 0 7 |
€ 2 6 0. 0 9 5 |
1 0 % |
€ 1 1. 8 1 6 |
5 % |
€ 1 4 7. 5 0 0 |
€ 2 5 8. 4 0 1 |
0, 7 5 |
1 6, 4 0 |
1, 1 7 |
| ( ) l. E En 1 |
€ 4 3, 5 0 |
€ 1 5 6. 0 0 6 |
% 2 5 |
€ 1 6. 1 9 3 |
% 1 0 |
€ 2 0 9. 8 6 0 |
€ 1 3 7. 1 1 5 |
0, 7 8 |
7, 4 7 |
1, 2 9 |
(1) EV and multiplies as for previous slide
(*) Revenue and Ebit annualized
El.En. SPA
Enrico ROMAGNOLI Investor Relations Managertel. +39 055-8826807E-mail: [email protected]
POLYTEMS HIR SRL
Bianca FERSINI MASTELLONI Financial CommunicationTel. +39 06-6797849 / +39 06-69923324E-mail: [email protected]
POLYTEMS HIR SRL
Silvia MARONGIUPress officeTel. +39 06-6797849 / +39 06-69923324E-mail: [email protected]